SCHEMBL6775381

SCHEMBL6775381

NC(=O)c1cccc2c1c1c(O)cc(-c3ccc(Cl)cc3)cc1n2Cc1cccc(C(F)(F)F)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
HTT P42858 1/20 0.44
ICMT O60725 6/20 0.43
PLA2G1B P04054 1/20 0.43
ATG4B Q9Y4P1 1/20 0.43
MAPT P10636 1/20 0.41
MAPK10 P53779 1/20 0.41
CCR1 P32246 1/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2B Q13224 1/20 0.41
F10 P00742 1/20 0.41
PARP1 P09874 1/20 0.40
LMNA P02545 1/20 0.40
XBP1 P17861 1/20 0.40
CNR1 P21554 1/20 0.40
PLA2G2A P14555 1/20 0.39
ATM Q13315 1/20 0.39
MAPK8 P45983 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6776400 0.92 MAPT (0.45) PPARGICMTMAPTMAPK10F10
SCHEMBL6690152 0.89 KDM4E (0.43) L3MBTL1ICMTPLA2G1BATG4BMAPT
SCHEMBL6776758 0.88 PLA2G2A (0.50) L3MBTL1PLA2G1BATG4BMAPTMAPK10
SCHEMBL6890365 0.88 PPARG (0.46) PPARGL3MBTL1HTTMAPTMAPK10
SCHEMBL6690216 0.88 PLA2G2A (0.43) PPARGL3MBTL1PLA2G1BPARP1PLA2G2A
SCHEMBL6772770 0.88 PLA2G2A (0.41) L3MBTL1ICMTPLA2G1BATG4BMAPT
SCHEMBL6776773 0.87 PLA2G2A (0.42) PPARGPLA2G1BPLA2G2A
SCHEMBL7966203 0.86 PLA2G2A (0.46) PPARGPLA2G1BPLA2G2A
SCHEMBL6693716 0.86 F10 (0.48) PPARGL3MBTL1ICMTPLA2G1BATG4B
SCHEMBL6775434 0.86 ADRA1D (0.46) L3MBTL1ICMTPLA2G1BATG4BMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed